$1,000 invested Merck & Co. Inc. (2016)
NYSE · MRK · reinvest dividends · adjusted close
●Result2016-01-04 — 2026-09-11
Today you would have
$3,944
+$2,944 (+294.41%)
MRKSPY (benchmark)
- Entry price
- $36.49
- Current price
- $143.93
- Shares
- 27.4026
- CAGR
- +13.70%
- Max Drawdown
- -43.44%
- vs SPY
- -55.42 pp
✦The story
Putting $1,000 into Merck & Co. in early 2016 would have produced $3,944 by mid-2026, a gain of +294.4%. Over that decade, Keytruda grew into one of the world's best-selling cancer therapies and became the company's central growth driver. The broader S&P 500 nonetheless did better, returning +349.8% over the same period.
#Related scenariosfor comparison
Other years for MRK